Notable Trends and Companies to Follow in Neuroscience
Historically, the approval rate for medicines treating central nervous system (CNS) disorders was low. By 2022, the success rate for CNS assets from phase 1 through to regulatory submission was only 5–6%.
The failure of pharmaceutical companies to bring CNS medications to the market can be attributed to factors such as a limited understanding of disease mechanisms and challenges in delivering drugs across the blood-brain barrier. Nevertheless, recent technological advancements and an improved understanding of disease pathophysiology led to expanding the CNS pipeline.
A recent report shows that the CNS pipeline has grown by 31%, constituting 14% of the overall industry R&D pipeline. Moreover, the approval of the first drug for spinal muscular atrophy (SMA) developed by Ionis Pharma and Biogen was a significant stride that revitalized interest in the field and demonstrated the ability of innovative treatments to address complex neurological disorders.
Topics: NeuroTech